{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:22:44Z","timestamp":1794504164887,"version":"4.9.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients in the lisocabtagene maraleucel (liso-cel) plus ibrutinib cohort of the phase 1\/2, open-label TRANSCEND CLL 004 study had relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) and received liso-cel (50 \u00d7 106 [dose level 1 (DL1)] or 100 \u00d7 106 [DL2] chimeric antigen receptor\u2013positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response\/remission (CR)\/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n = 5; DL2, n = 51), median age was 64.5 years (range, 44-77), 98% had high-risk cytogenetics, and median number of prior therapies was 5 (range, 1-13). Median follow-up was 24.8 months (range, 3.1-51.8). At DL2, CR\/CRi rate was 45% (95% confidence interval [CI], 31-60), and overall response rate was 86% (95% CI, 74-94). Median duration of response was not reached (NR; 95% CI, 28.7 to NR) for patients with CR\/CRi. Median progression-free survival was 31.4 months (95% CI, 20.1 to NR). In DL1 plus DL2, the most common grade \u22653 treatment-emergent adverse events (TEAEs) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of the patients (grade 3, 4%; no grade 4\/5), and neurological events were reported in 41% (grade 3\/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of the patients (grade 3\/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with R\/R CLL\/SLL with predictable and manageable safety. This trial was registered at www.clinicaltrials.gov as NCT03331198 and NCT03435796.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033565","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:58:50Z","timestamp":1785265130000},"page":"2462-2476","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Lisocabtagene maraleucel combined with ibrutinib in R\/R CLL or SLL: primary results from TRANSCEND CLL 004"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-270X","authenticated-orcid":false,"given":"William G.","family":"Wierda","sequence":"first","affiliation":[{"name":"1The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-8573","authenticated-orcid":false,"given":"Kathleen","family":"Dorritie","sequence":"additional","affiliation":[{"name":"2UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8409","authenticated-orcid":false,"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[{"name":"3Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneesh","family":"Nath","sequence":"additional","affiliation":[{"name":"4Banner MD Anderson Cancer Center, Gilbert, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-4549","authenticated-orcid":false,"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"5Moores UC San Diego Cancer Center, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[{"name":"6David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert A.","family":"Eradat","sequence":"additional","affiliation":[{"name":"7Santa Monica Cancer Center, University of California, Los Angeles, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[{"name":"8Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"9Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Solomon","sequence":"additional","affiliation":[{"name":"11Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[{"name":"12Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Ermann","sequence":"additional","affiliation":[{"name":"12Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Arnason","sequence":"additional","affiliation":[{"name":"13Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-8871","authenticated-orcid":false,"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[{"name":"14Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[{"name":"15John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Andreadis","sequence":"additional","affiliation":[{"name":"16Division of Hematology\/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monalisa","family":"Ghosh","sequence":"additional","affiliation":[{"name":"17Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-5486","authenticated-orcid":false,"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"18Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"19Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-7385","authenticated-orcid":false,"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[{"name":"20Division of Transplant and Cell Therapy, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"21Division of Hematology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-6819","authenticated-orcid":false,"given":"Jacob","family":"Soumerai","sequence":"additional","affiliation":[{"name":"22Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-6211","authenticated-orcid":false,"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[{"name":"23Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherilyn A.","family":"Tuazon","sequence":"additional","affiliation":[{"name":"24Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena K.","family":"Perna","sequence":"additional","affiliation":[{"name":"25Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-San","family":"Ou","sequence":"additional","affiliation":[{"name":"24Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revathi","family":"Ananthakrishnan","sequence":"additional","affiliation":[{"name":"25Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Rane","sequence":"additional","affiliation":[{"name":"25Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eniko","family":"Papp","sequence":"additional","affiliation":[{"name":"24Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Ansari","sequence":"additional","affiliation":[{"name":"24Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan G.","family":"Thompson","sequence":"additional","affiliation":[{"name":"24Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abood","family":"Okal","sequence":"additional","affiliation":[{"name":"26Bristol Myers Squibb, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Peiser","sequence":"additional","affiliation":[{"name":"24Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1782-6709","authenticated-orcid":false,"given":"Yizhe","family":"Chen","sequence":"additional","affiliation":[{"name":"26Bristol Myers Squibb, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9469-5061","authenticated-orcid":false,"given":"Sanhita","family":"Sengupta","sequence":"additional","affiliation":[{"name":"25Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0931-4201","authenticated-orcid":false,"given":"Pradipta","family":"Ray","sequence":"additional","affiliation":[{"name":"25Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixian","family":"Wang","sequence":"additional","affiliation":[{"name":"27Bristol Myers Squibb, Boudry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8298","authenticated-orcid":false,"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"28City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10254","key":"2026111211265666300_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"2026111211265666300_bib2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026111211265666300_bib3","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"2026111211265666300_bib4","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10402","key":"2026111211265666300_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"2026111211265666300_bib6","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026111211265666300_bib7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026111211265666300_bib8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood-2023-179529","article-title":"Lisocabtagene maraleucel (liso-cel) in R\/R CLL\/SLL: 24-month median follow-up of TRANSCEND CLL 004 [abstract]","volume":"142","author":"Siddiqi","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2026111211265666300_bib9","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3324\/haematol.2020.267914","article-title":"T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective","volume":"106","author":"Peters","year":"2021","journal-title":"Haematologica"},{"key":"2026111211265666300_bib10","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"2026111211265666300_bib11","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/s41409-021-01420-9","article-title":"Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"56","author":"Mohty","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2026111211265666300_bib12","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"15","key":"2026111211265666300_bib13","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2026111211265666300_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J Immunother"},{"issue":"19","key":"2026111211265666300_bib15","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2026111211265666300_bib16","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026111211265666300_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-140622","article-title":"Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) [abstract]","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2026111211265666300_bib18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2026111211265666300_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2026111211265666300_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"issue":"9","key":"2026111211265666300_bib21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2026111211265666300_bib22","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"suppl 2","key":"2026111211265666300_bib23","first-page":"A477","article-title":"Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy","volume":"9","author":"Thorpe","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"2026111211265666300_bib24","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies [abstract]","volume":"132","author":"Kaptein","year":"2018","journal-title":"Blood"},{"key":"2026111211265666300_bib25","doi-asserted-by":"crossref","first-page":"15330338221133224","DOI":"10.1177\/15330338221133224","article-title":"Synergistic effects of zanubrutinib combined with CD19 CAR-T cells in Raji cells in vitro and in vivo","volume":"21","author":"Ye","year":"2022","journal-title":"Technol Cancer Res Treat"},{"issue":"2","key":"2026111211265666300_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"issue":"14","key":"2026111211265666300_bib27","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.3390\/cancers15143648","article-title":"Non-covalent Bruton's tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia","volume":"15","author":"Montoya","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026111211265666300_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2026111211265666300_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"2026111211265666300_bib30","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2026111211265666300_bib31","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2026111211265666300_bib32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/20\/2462\/2599869\/blood_bld-2026-033565-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/20\/2462\/2599869\/blood_bld-2026-033565-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:27:07Z","timestamp":1794500827000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/20\/2462\/569901\/Lisocabtagene-maraleucel-combined-with-ibrutinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,12]]},"references-count":32,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,11,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033565","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,12]]},"published":{"date-parts":[[2026,11,12]]}}}